Results 251 to 260 of about 93,479 (280)

Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene

International Journal of Oncology, 1997
Experiments were designed to investigate immunogenicity and therapeutic efficacy of tumour vaccines constructed by transfection of poorly immunogenic murine sarcoma Mc12 with synergistic CD80 and IL-2 genes. Immunization/challenge experiments demonstrated that both, IL-2(+) and IL-2(+) plus CD80(+) live cell vaccines can exert an immunizing stimulus ...
J, Bubenik, P, Rossner, D, Bubenikova, J, Simova, M, Indrova, E, Sloncova   +5 more
openaire   +2 more sources

CD80 and CD86 polymorphisms in populations of various ancestries: 5 new CD80 promoter alleles

Human Immunology, 2012
CD80 and CD86 are closely linked genes on chromosome 3 that code for glycoproteins of the immunoglobulin superfamily, expressed on the surface of antigen-presenting cells. These costimulatory molecules play essential roles for stimulation and inhibition of T cells through binding to CD28 and CTLA-4 receptors.
Márcia Holsbach, Beltrame, Márcia Regina, Pincerati, Ricardo, Dalla-Costa, Roseli, Wassem, Karen Francine, Köhler, Eleidi Alice, Chautard-Freire-Maia, Luiza Tamie, Tsuneto, Maria Luiza, Petzl-Erler   +7 more
openaire   +2 more sources

Two Regions in the CD80 Cytoplasmic Tail Regulate CD80 Redistribution and T Cell Costimulation

The Journal of Immunology, 1998
AbstractCD28 is a major T cell costimulatory molecule, delivering signals distinct from those of the CD3/TCR complex, which regulate cytokine and cytokine receptor expression, cell proliferation, and cell viability. CD28 needs to be cross-linked to initiate signals, yet both of its ligands, CD80 and CD86, are expressed as monomers.
R T, Doty, E A, Clark
openaire   +2 more sources

CD80/86 Inhibitors: Abatacept

2016
CD80/CD86 inhibitors are protein constructs which bind and inactivate CD80/CD86 on the surfaces of antigen-presenting B-cells and monocytes, blocking the costimulatory signal between these cells and CD28 on T-cells that is the second message of T-cell receptor/MHC interaction.
Pile, Kevin (R17082), Graham, Garry G., Mahler, Stephen M.   +2 more
openaire   +2 more sources

Expression of CD80 promoter in transgenic mice

Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2000
CD80 is a very potent co-stimulatory factor which is required for complete T-cell activation. Here, we use transgenic mice as a tool to map the promoter of the CD80 gene. We engineered three different CD80 promoter driven luciferase transgenes: -3084, -1073 and -215. With these transgenes, we have generated three groups of transgenic mice.
H, Zhang, D, Haasch, B, Patterson, B, Dickinson, G F, Okasinski   +4 more
openaire   +2 more sources

CD28–CD80/CD86 Interactions in testicular immunoregulation

Journal of Reproductive Immunology, 1996
The expression of two accessory molecules on antigen-presenting cells (APC), the CD80/ B7-1 and CD86/B7-2 antigens, was studied in the testis of normal and non-obese diabetic (NOD) mice. In addition, the effect of CD28 stimulation on suppression of lymphocytes by testicular products was investigated.
S, Sainio-Pöllänen, T, Saari, O, Simell, P, Pöllänen   +3 more
openaire   +2 more sources

CD80 Dimerization with PD-L1 in Cis Disrupts CTLA4–CD80 Interactions

Cancer Discovery, 2020
Abstract PD-L1 can repress the CTLA4 axis to stimulate an immune response.
openaire   +1 more source

CD80 Expression on Monocytes in HIV-Infected Patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1997
A prominent feature of HIV infection is a progressive anergy of T cells and an increase of activation-dependent T-cell death. CD80 (B7.1), the ligand of CD28, is an important co-stimulatory molecule on antigen-presenting cells that delivers an essential second signal for T-cell activation. To test whether immunologic dysfunction in HIV disease involves
P, Löw, C, Weber, E, Harrer, P, Rohwer, J R, Kalden, T, Harrer   +5 more
openaire   +2 more sources